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Skin disordersMolecular-targeted therapies with tyrosine kinase inhibitors (TKIs) have provided a major breakthrough in can-
cer treatment. These agents are given orally and demonstrated to be substrates for drug transporters. In clinical
settings, TKIs are mainly used at a ﬁxed dose, but wide interpatient variability has been observed in their phar-
macokinetics and/or pharmacodynamics. Genetic polymorphisms of ABC transporters, drug-drug interaction
and adherence are among the factors causing such variation. To overcome these problems, therapeutic drug
monitoring has been applied in clinical practice for patient care. Skin disorders are frequently observed as adverse
drug reactions when using TKIs, and are commonly managed by symptomatic therapy based on clinical experi-
ence. Recent studies have provided some insights into the molecular mechanisms underlying skin disorders in-
duced by TKIs. This review article summarizes the accumulated clinical and basic pharmacological evidence of
TKIs, focusing on erlotinib, sorafenib and sunitinib.
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Recent progress in the development of molecular-targeted agents
has expanded the treatment options for patients with various carcino-
mas, such as lung cancer (Bezjak et al., 2006; Shepherd et al., 2005),
renal cell carcinoma (Motzer et al., 2007) and hepatocellular carcinoma
(Cheng et al., 2009; Llovet et al., 2008). Molecular-targeted therapies
with tyrosine kinase inhibitors (TKIs) are designed to disrupt signaling
pathways responsible for the abnormal proliferation of cancer cells,
and most TKIs are administered orally. In general, drug efﬁcacy and
safety are determined by the interplay of multiple processes that regu-
late pharmacokinetics (e.g., absorption, distribution, metabolism and
excretion) and pharmacodynamics (e.g., drug action). For orallythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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intestinal absorption and distribution before elimination via metabolic
and excretory pathways (Klümpen et al., 2011). Although drug-
metabolizing enzymes have been believed to be key determinants of
pharmacokinetics, the membrane transport processes mediated by
drug transporters are also recognized as important to pharmacokinetic
properties.
In clinical practice, oncologists expend substantial effort to treat
patients by optimally selecting and dosing TKIs, in order to increase
the efﬁcacy and to reduce adverse drug reactions (ADRs). To obtain
optimal drug efﬁcacy, pharmacodynamic variations such as gene
mutations and the expression levels of certain target molecules
[e.g. epidermal growth factor receptor (EGFR) and human epidermal
growth factor receptor 2] have been tested in the practice. To correct
for pharmacokinetic variation, traditional cytotoxic chemotherapeu-
tic agents are administered according to the patient’s body surface
area, even though this approach does not substantially reduce
interpatient variability of chemotherapy cytotoxicity (Baker et al.,
2002). On the other hand, TKIs are orally given on a daily basis
(with or without a drug holiday) at ﬁxed doses, and such ﬁxed dos-
ing may cause much larger variation between individuals in terms
of clinical efﬁcacy and toxicity (Gao et al., 2012). It has been widely
recognized that renal and/or hepatic functions, genetic background,
adherence to treatment and nongenetic factors (drug-drug interac-
tions and drug-food interactions) can cause pharmacokinetic varia-
tion of TKIs by changing drug exposure (Klümpen et al., 2011).
Among these factors, genetic polymorphism of breast cancer resis-
tance protein (BCRP/ABCG2) has been reported to have a major im-
pact on the drug exposure of many TKIs (Fukudo et al., 2013;
Mizuno et al., 2010, 2012, 2014).
Under these circumstances, various efforts to achieve optimal dosing
have been attempted, including dose individualization of TKIs, such as
phenotype-guided dosing, genotype-guided dosing, toxicity-adjusted
dosing and therapeutic drug monitoring (TDM) (Klümpen et al.,
2011). Considering applications in clinical practice, TDM is a very prom-
ising strategy and recent evidence indicates that certain pharmacoki-
netic parameters, including trough levels, are correlated with clinical
outcomes for many TKIs, such as imatinib, erlotinib, sorafenib and suni-
tinib (Gao et al., 2012; Yu et al., 2014). Furthermore, the molecular
mechanisms of adverse reactions of TKIs have been partly elucidated
by basic and in silico pharmacology.
It is likely that the pharmacotherapy of TKIs is evolving year by year
to resolve the clinical problems in daily practice, by adopting recent
basic and clinical pharmacological evidence. This article is focused on
reviewing such evidence, concentrating on three kinds of TKI: erlotinib,
sorafenib and sunitinib. These drugs have been used as the ﬁrst-line
therapy to treat patientswith non-small cell lung cancer (NSCLC), hepa-
tocellular carcinoma (HCC), differentiated thyroid cancer ,and renal cell
carcinoma (RCC), and extensive information including on drug trans-
porters affecting their pharmacokinetic variation and the molecular
mechanisms of their skin disorders has recently been accumulated.
2. Effect of drug-metabolizing enzymes and transporters
Most TKIs are oral drugs given daily as a single agent at a ﬁxed dose.
Oral administration should be processed by intestinal absorption,
namely, intestinal inﬂux and efﬂux steps, which could be mediated by
drug transporters. Although it is not necessary to take this process
into consideration for classical injectable anticancer agents, the intesti-
nal absorption process should cause large pharmacokinetic variability,
probably due to fat content within food, coadministration with gastric
acid-reducing drugs and the functional ability of intestinal drug trans-
porters that have recently been identiﬁed. In this section, ﬁrst, we sum-
marize the pharmacokinetic factors that regulate the drug disposition of
erlotinib, sorafenib and sunitinib, with an intensive focus on intestinal
efﬂux drug transporters (Table 1).2.1. Erlotinib
Erlotinib is metabolized in the liver, mainly by cytochrome P450
(CYP) 3A4/3A5 and, to a lesser extent, by CYP1A1/1A2, to produce
the active metabolite OSI-420 (desmethyl erlotinib, M14), followed
by the formation of many other metabolites, including oxidative me-
tabolites (Li et al., 2007a; Ling et al., 2006). Erlotinib and OSI-420 are
considered to be equipotent in inhibiting EGFR tyrosine kinase
activity.
In vitro transport studies have demonstrated that erlotinib is a
substrate for P-glycoprotein (P-gp/ABCB1) and breast cancer resis-
tance protein (BCRP/ABCG2), but not for multidrug resistance-
associated protein 2 (MRP2/ABCC2) (Elmeliegy et al., 2011;
Marchetti et al., 2008). ATP binding cassette membrane transporters,
including ABCB1 and ABCG2, are expressed in normal tissues includ-
ing the small intestine, liver, kidney and blood–brain barrier (BBB)
(Glavinas et al., 2004), and are responsible for regulating the oral ab-
sorption, biliary and urinary secretion, and penetration of BBB for
several anticancer drugs including TKIs (Agarwal et al., 2010;
Kodaira et al., 2010; Kunimatsu et al., 2013; Lagas et al., 2010;
Mizuno et al., 2012; Oostendorp et al., 2009; Polli et al., 2009). Fur-
thermore, the pharmacokinetic roles of ABCB1 and ABCG2 were
also assessed using gene-disrupted mice, namely, Abcg2−/−,
Abcb1a/1b−/− and Abcg2−/−/Abcb1a/1b−/− (triple-knockout) mice.
When erlotinib was given orally to Abcg2−/−/Abcb1a/1b−/− mice, it
was found that its area under the curve (AUC) was about 50% higher
in the triple-knockout mice than in wild-type ones (Marchetti et al.,
2008). These ﬁndings suggest that ABCB1 and ABCG2 play pivotal
roles in restricting the intestinal absorption of erlotinib. Further evi-
dence of these transporters’ contribution was obtained by
pharmacogenomic analyses, which are introduced in Sections 3.1
and 3.2. A recent study has also indicated that erlotinib and OSI-
420 are substrates for the uptake transporters organic anion trans-
porter 3 (OAT3/SLC22A5) and organic cation transporter 2 (OCT2/
SLC22A2), but their pharmacokinetics and clinical implications
have not been fully elucidated (Elmeliegy et al., 2011).2.2. Sorafenib
Sorafenib is primarily metabolized in the liver, by CYP3A4-mediated
oxidation and uridine diphosphate glucuronosyltransferase (UGT)
1A9-mediated glucuronidation. Sorafenib N-oxide (M-2), the major
active CYP3A4 metabolite, has been reported to represent approxi-
mately 10% of the circulating sorafenib concentration in plasma
(Clark et al., 2005).
In vitro transport studies have demonstrated that sorafenib was
moderately transported by ABCB1 and more efﬁciently by ABCG2
(Gnoth et al., 2010; Hu et al., 2009; Lagas et al., 2010; Tang et al.,
2013). When sorafenib was orally administered to Abcg2−/−, Abcb1a/
1b−/− and Abcg2−/−/Abcb1a/1b−/−mice, the systemic exposure upon
oral administration did not differ among all strains. However, brain ac-
cumulation was 4.3-fold increased in Abcg2−/− mice and 9.3-fold in-
creased in Abcg2−/−/Abcb1a/1b−/− mice (Lagas et al., 2010). This
suggests that intestinal ABCB1 and ABCG2 do not play a major role in
the oral bioavailability of sorafenib, but are responsible for its brain
accumulation.
To understand the hepatic disposition of sorafenib, because this
drug is used for HCC, in vitro and in vivo transport studies were car-
ried out. As a result, organic cation transporter 1 (OCT1, SLC22A1)
and organic anion transporting polypeptides OATP1B1 (SLCO1B1)
and OATP1B3 (SLCO1B3) were shown to be responsible for the sinu-
soidal membrane transport of sorafenib (Herraez et al., 2013; Swift
et al., 2013; Zimmerman et al., 2013). Clinical pharmacogenomic
studies have also demonstrated that hepatic OCT1 may be responsi-
ble for the efﬁcacy of sorafenib for HCC (see Section 3.2).
Table 1
ABC drug transporters involved in the pharmacokinetics of erlotinib, sorafenib and sunitinib.
Drug Transporter Transport-disrupted animal model Orally systemic exposed AUC




Erlotinib ABCB1 Abcb1a/1b−/− − 295% Kodaira et al., 2010
ABCG2 Abcg2−/− − 129% Marchetti et al., 2008
Triple-knockout (Abcg2−/−/Abcb1a/b−/−) 150% 852% Marchetti et al., 2008
Sorafenib ABCB1 Abcb1a/1b−/− No difference No difference Lagas et al., 2010
ABCG2 Abcg2−/− No difference 430% Lagas et al., 2010
Triple-knockout (Abcg2−/−/Abcb1a/b−/−) No difference 930% Lagas et al., 2010
Sunitinib ABCB1 Abcb1a/1b−/− 376% 160% Mizuno et al., 2012
ABCG2 Abcg2−/− 297% 580% Mizuno et al., 2012
Triple-knockout (Abcg2−/−/Abcb1a/b−/−) 267% 2400% Mizuno et al., 2012
ABCB1: P-glycoprotein (P-gp) ABCG2: breast cancer resistance protein (BCRP).
AUC: area under the curve.
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Sunitinib is primarily metabolized by CYP3A4 to the equally active
SU12662. SU12662 is further metabolized to inactive moieties by
CYP3A4 (Adams and Leggas, 2007).
In vitro transport studies have demonstrated that sunitinib is a sub-
strate for ABCB1 and ABCG2 (Hu et al., 2009; Mizuno et al., 2010). The
pharmacokinetic role of ABCG2 and ABCB1 was also shown using
Abcg2−/−, Abcb1a/1b−/− and Abcg2−/−/Abcb1a/1b−/− mice (Mizuno
et al., 2012; Tang et al., 2012, 2013). For example, we demonstrated
that the maximum concentration and AUC0–4 of sunitinib were signiﬁ-
cantly higher in Abcg2−/−, Abcb1a/1b−/− and Abcg2−/−/Abcb1a/1b−/−
mice than inwild-type oneswhen sunitinibwas given orally, but not in-
traperitoneally (Mizuno et al., 2012). The systemic exposure of sunitinib
was higher in Abcb1a/1b−/−mice than in wild-type mice when suniti-
nib was given orally, although a clinical pharmacogenomic study sug-
gested that the ABCB1 1236TT-2677TT-3435TT haplotype was not
associated with systemic exposure to sunitinib (Mizuno et al., 2012).
This study also reported thatABCG2 c.421C N Apolymorphismwas asso-
ciatedwith increased sunitinib exposure in RCCpatients. Furthermore, a
population pharmacokinetic analysis demonstrated that ABCG2
421C N A is a predictive covariate for the oral clearance of sunitinib
(Mizuno et al., 2014).3. Factors causing pharmacokinetic variation
3.1. Genetic polymorphisms of ABCG2 c.421C N A
In 2013, the International Transporter Consortium selected and
commented on two clinically important transporter polymorphisms
for drug development: OATP1B1 (SLCO1B1 c.521 T N C) and BCRP
(ABCG2 c.421C N A) (Giacomini et al., 2013). As described in
Section 2, ABCG2 is an efﬂux transporter, which consists of 655
amino acids and is involved in the cellular efﬂux of various drugs includ-
ing TKIs. A nonsynonymous SNP, c.421C N A (p.Q141K), localized in the
ATP-binding domain, is associated with impaired activity in vitro
(Furukawa et al., 2009). Early pharmacogenetic studies regarding
ABCG2 polymorphisms demonstrated that ABCG2 c.421C N A is linked
to the increased plasma exposure of several drugs, such as diﬂomotecan
(Sparreboom et al., 2004), rosuvastatin (Zhang et al., 2006) and
sulfasalazine (Yamasaki et al., 2008).With regard to TKIs, it has been re-
ported that the heterozygous variant of ABCG2 c.421C N Awas associat-
ed with higher exposure and toxicity of geﬁtinib (Li et al., 2007b) and
erlotinib (Thomas et al., 2009).
We previously experienced an RCC patient with many severe ad-
verse events, such as facial acne, hypothyroidism and thrombocytope-
nia, early after the start of sunitinib therapy (Mizuno et al., 2010).
Pharmacokinetic analyses revealed that this patient had been exposed
to 2.5-fold-higher sunitinib compared with another 4 patients, and
that the genotype of the ABCG2 c.421C N A polymorphism in this patientwas a homozygous variant, whereas the other patients were heterozy-
gous or wild type. These relationships were also conﬁrmed in more
Japanese (Mizuno et al., 2012) and Korean metastatic RCC patients
(Kim et al., 2013). Furthermore, a population pharmacokinetic analysis
also demonstrated that the ABCG2 c.421C N A genotype is a predictive
covariate for the oral clearance of sunitinib (Mizuno et al., 2014).
These pharmacogenomic studies, together with in vitro and in vivo suni-
tinib transport studies, revealed that sunitinib is a substrate of ABCG2
and loss of its function due to ABCG2 c.421C N A can lead to an increase
in systemic exposure to sunitinib (Fig. 1).
Sunitinib-related toxicitywasmore frequently observed in Asian pa-
tients than in non-Asian ones (Gore et al., 2009; Hong et al., 2009;
Motzer et al., 2007; Uemura et al., 2010; Yoo et al., 2010). In contrast
to Asian patients, the impacts of the ABCG2 c.421C N A genotype on su-
nitinib efﬁcacy and toxicity were not identiﬁed in European patients
(Diekstra et al., 2014; Garcia-Donas et al., 2011; van der Veldt et al.,
2011; van Erp et al., 2009). Interestingly, ABCG2 c.421C N A appears to
be more common in Asians (allele frequency, 26.6-35.0%); on the
other hand, this allele is very rare in sub-Saharan African (1.0%) and
Caucasian populations (7.4-11.1%) (Giacomini et al., 2013). These re-
sults suggest that ABCG2 c.421C N A is one of the reasons for the ethnic
difference in sunitinib pharmacokinetics and toxicity.
As erlotinib is a substrate for ABCG2, we further investigated
whether ABCG2 c.421C N A can inﬂuence the clearance of erlotinib
in NSCLC patients. As expected, ABCG2 c.421C N A polymorphism
was demonstrated to be a signiﬁcant determinant of interindividual
variability in the apparent clearance of erlotinib (Fukudo et al.,
2013). Another pharmacogenetic analysis in Japanese NSCLC cases
showed that high exposure to erlotinib related to ABCG2 c.421C N A
predisposed patients to drug-induced severe interstitial lung disease
(Fujita et al., 2014). Similarly to the case for sunitinib, the ABCG2
c.421C N A genotype appeared not to be a signiﬁcant determinant
of erlotinib pharmacokinetics in non-Asian patients (Rudin et al.,
2008; White-Koning et al., 2011).
3.2. Other genetic polymorphisms besides ABCG2 c.421C N A
Erlotinib has been reported to be a substrate for ABCB1, as well as
ABCG2 (Marchetti et al., 2008). The ABCB1 TTT haplotype (1236 T,
2677 T and 3435 T)was previously shown to be associatedwith low ex-
pression of ABCB1 (Kimchi-Sarfaty et al., 2007). A clinical study demon-
strated that the trough concentration of erlotinib at a steady state in
NSCLC patients with the ABCB1 1236TT-2677TT-3435TT genotype was
higher than in other groups, and that patients carrying this genotype
had a higher risk of developing grade ≥2 toxicity (Hamada et al., 2012).
In a pharmacogenomic study of sorafenib, it was demonstrated that
UGT1A9 2152 C N T polymorphism was independently associated with
grade ≥2 diarrhea induced by sorafenib (Boudou-Rouquette et al.,
2012a). Recently, OCT1 has been reported to be involved in sorafenib
uptake by hepatocytes (Swift et al., 2013). Furthermore, in vitro study
indicated that two OCT1 variants, SLC22A1 c.181C N T and SLC22A1
Fig. 1. Relationship between intestinal absorption of sunitinib and ABCG2 c.421C N A. On the basis of in vitro, in vivo and clinical studies as well as the biochemical properties of ABCG2
c.421C N A (p.Q141K), ABCG2 could function as a barrier to the intestinal absorption of sunitinib.
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reach an active intracellular concentration in HCC and cholangiocarci-
noma (CGC) (Herraez et al., 2013). These results suggest that an aber-
rant OCT1 variantmay affect the responses of HCC and CGC to sorafenib.
A pharmacogenomic study of sunitinib has suggested that polymor-
phism in CYP3A5*1 is associated with a need for dose reduction due to
severe toxicities, and is a predictive factor for prolonged progression-
free survival time (PFS) in patients with RCC (Garcia-Donas et al., 2011).
3.3. Factors identiﬁed by population pharmacokinetic analyses
Large interindividual variability in TKI exposure has been observed
(Faivre et al., 2006; Gao et al., 2012; Minami et al., 2008). The pheno-
types of the pharmacokinetics of TKIs are multifactorial, and several
studies have reported that genetics, drug-drug interactions, poor
adherance and environment could have an impact on the pharmaco-
kinetics of TKIs, including erlotinib, sorafenib and sunitinib. A popu-
lation pharmacokinetic approach has been widely used to develop a
model to describe the pharmacokinetics of drugs and identiﬁed po-
tential covariates responsible for pharmacokinetic variability in the
target patient population. In this section, we introduce the results
of population pharmacokinetic analysis of TKIs, especially erlotinib,
sorafenib and sunitinib.
A population pharmacokinetic analysis of erlotinib in 42 patients
with head and neck squamous cell carcinoma indicated that the covar-
iates retained to predict erlotinib clearancewere alanine aminotransfer-
ase, age and ABCG2 c.421C N A (Thomas et al., 2009). In patients with
lung cancer, the ABCG2 c.421C N A polymorphismwas found to be asso-
ciated with low apparent oral clearance of erlotinib by a population
pharmacokinetic approach (Fukudo et al., 2013).
A recent population pharmacokinetic study of sorafenib in 111 pa-
tients reported the lack of any effect of genotype with respect to
CYP3A4*1B, CYP3A5*3C, UGT1A9*3 and UGT1A9*5 on the disposition of
sorafenib (Jain et al., 2011). Namely, none of these pharmacogenetic
variants was associated with sorafenib pharmacokinetics.
In several population pharmacokinetic studies, factors affecting su-
nitinib pharmacokinetics were reported. One population pharmacoki-
netic study reported that environmental covariates, including tumor
type, race, gender, body weight and elevated Eastern Cooperative On-
cology Group score, could only explain 2-17% of the observed changes
in AUC and/or Cmax (Houk et al., 2009). These ﬁndings indicate that
the individual covariates investigated minimally affected sunitinib
pharmacokinetics. Additionally, we suggested that signiﬁcantly higher
AUC andmore toxicity were observed in patients with efﬂux transport-
er ABCG2 421C/A or CC (Mizuno et al., 2012). From this result, we quan-
titatively evaluated the effect of potential predictive factors including
ABCG2 genotype on the pharmacokinetics of sunitinib by a populationpharmacokinetic approach (Mizuno et al., 2014). From the results, the
ABCG2 c.421C N A genotype was identiﬁed as a signiﬁcant covariate for
prediction of the oral clearance of sunitinib, suggesting that the assess-
ment of the ABCG2 421C N A genotype could be helpful for identifying
patients at high risk of increased exposure to sunitinib.
3.4. Drug-drug interaction
Data on the effects of the coadministration of TKIs with CYP3A4 in-
ducers or inhibitors have been veriﬁed in a clinical trial. Here, we
show some typical drug-drug interaction results (Table 2). Furthermore,
as the solubility of oral TKIs depends on the gastric pH, we also summa-
rize the inﬂuences of concomitant food intake and histamine H2-
receptor antagonist (H2 blockers)/proton pump inhibitors (PPIs) for
TKIs in Table 2.
CYP3A4 inducer and inhibitor have profound effects on the erlotinib
AUC (Johnson et al., 2005; Rakhit et al., 2008). These ﬁndings indicate
that CYP3A4 inducer and inhibitor should be used with extensive cau-
tion when combined with erlotinib. The solubility of erlotinib decreases
above pH5 (Duong and Leung, 2011), indicating that a decrease in acid
secretion could contribute to decreased solubility and absorption of er-
lotinib. As expected, concomitant use of erlotinib with omeprazole,
which inhibits gastric secretion for N24 h after dosing, resulted in a
marked decrease in the absorption and bioavailability of erlotinib.
Similary, concomitant use of erlotinib with ranitidine at 300 mg once
daily led to a signiﬁcant decrease in erlotinib exposure. On the other
hand, when erlotinib was given for 2 hwithin 10 h after the administra-
tion of ranitidine at 150 mg twice a day, staggered administration
caused a slight reduction of erlotinib exposure (Budha et al., 2012).
These interactions are explained by the fact that H2 blockers reduce
gastric secretion for b12 h after dosing. We also observed no signiﬁcant
pharmacokinetic interaction between erlotinib and gastric acid-
reducing agents, which may be due to their administration in a stag-
gered manner (Fukudo et al., 2013). Since food increases the bioavail-
ability, erlotinib should be taken at least 1 h before or 2 h after eating.
Furthermore, the pharmacokinetic proﬁle of erlotinib was found to be
signiﬁcantly changed by smoking (Hamilton et al., 2006). This is proba-
bly due to the induction of CYP1A1/2, which is known to be unregulated
in smokers.
Sorafenib concentration has been reported to be decreased by a
CYP3A4 inducer, rifampicin (Keating and Santoro, 2009). A previous
case report presented that plasma sorafenib concentration was in-
creased by inhibiting CYP3A4 in combination with the calcium-
channel blocker felodipine in a patient with HCC (Gomo et al., 2011).
In contrast, another study reported that the potent CYP3A4 inhibitor ke-
toconazole did not affect the plasma concentration of sorafenib (Lathia
et al., 2006). These studies show that the pharmacokinetic interaction
Table 2
Factors causing pharmacokinetic variation of erlotinib, sorafenib and sunitinib.
Drug Erlotinib Sorafenib Sunitinib




CYP3A4 inhibitors/inducers* Rifampicin AUC 33%, Cmax 71%d Rifampicin AUC 63%h Rifampicin AUC 54%, Cmax 77%n
Ketoconazole AUC 186%, Cmax 202%e No effect of ketoconazolei Ketoconazole AUC 151%, Cmax149%n
grapefruit juice AUC 111%o
PPIs/H2 inhibitors* Omeprazole AUC 54%, Cmax 39% (Concomitant)f No effectf No effectf
Ranitidine AUC 67%, Cmax 56% (Concomitant)f
Ranitidine AUC 83%, Cmax 85% (Staggered; erlotinib,
2 h before and 10 h after ranitidine)f
Fasting/Fed* AUC Cmax 133% (food intake)g Recommended without foodj No inﬂuencep
*Compared with control PPIs: proton pump inhibitors H2 inhibitors: histamine H2-receptor antagonists AUC: area under the curve.
Data compiled from a, Fukudo et al., 2013; b, Fujita et al., 2014; c, Hamada et al., 2012; d, Johnson et al., 2005; e, Rakhit et al., 2008; f, Budha et al., 2012; g, Ling et al., 2008; h, Keating &
Santoro, 2009; i, Lathia et al., 2006; j, Kane et al., 2006; k, Mizuno et al., 2010; l, Mizuno et al., 2012; m,Mizuno et al., 2014; n, Adams and Leggas, 2007; o, van Erp et al., 2011; p, Bello et al.,
2006.
129T. Terada et al. / Pharmacology & Therapeutics 152 (2015) 125–134between sorafenib and coadministered drugs metabolized by CYP3A4
remains controversial. In addition, no clinically meaningful change in
sorafenib with the concomitant administration of esomeprazole was
observed (Zhang et al., 2014). This result indicates that antacids, such
as H2 blockers and PPIs, can be used concomitantly with sorafenib.
With a high-fat meal, sorafenib bioavailability was reduced 29% com-
pared with its fasting bioavailability (Kane et al., 2006).
Concomitant dosingwith a CYP3A4 inducer or inhibitor caused a no-
table change in the AUC of sunitinib (Adams and Leggas, 2007). Because
sunitinib solubility does not decline until pH6.8, no effect on sunitinib
would be expected during treatment with H2 blockers or PPIs (van
Leeuwen et al., 2014). The effects of food on the AUC of sunitinib were
determined, and did not impact on the pharmacokinetics of sunitinib
and its metabolite SU12662 (Bello et al., 2006). However, we should
be aware that the AUC of sunitinib increased by 11% in combination
with grapefruit juice, which is an intestinal CYP3A4 inhibitor (van Erp
et al., 2011).3.5. Adherence
Asmentioned later, the application of TDMduring oral TKIs pharma-
cotherapies provides cancer patients with better quality of life com-
pared with conventional cytotoxic chemotherapies. However, drug
adherence is becoming a critical issue. Several studies have reported
that poor adherence could lead to a suboptimal response to imatinib
(Marin et al., 2010; Noens et al., 2009). Namely, patients with an adher-
ence rate N 90% had signiﬁcantly higher rates of major molecular re-
sponse (MMR) and complete molecular response (CMR) than patients
with ≤90% (MMR: 94.5% vs. 28.4%, p b 0.001; CMR: 43.8% vs. 0%, p =
0.002) during imatinib therapy (Marin et al., 2010). Therefore, for
other oral targeted agents, including erlotinib, sorafenib and sunitinib,
poor adherence may be the predominant reason for the inability to ob-
tain adequate responses. To overcome this problem, the TDM of TKIs
could be a convenient tool for conﬁrming patient adherence.Table 3
Current doses and interpatient pharmacokinetic variations of erlotinib, sorafenib and sunitinib
Drug Dosage per day (indications) Interpatien
coefﬁcient
AUC
Erlotinib 150 mg (NSCLC) 64%
Sorafenib 800 mg (RCC, HCC) 39-82%
Sunitinib 50 mg (RCC, GIST) 41%
NSCLC: non-small cell lung cancer RCC: renal cell carcinoma HCC: hepatocellular carcinoma GI4. Therapeutic drug monitoring
Retrospective studies have shown that targeted drug exposure,
reﬂected in the AUC, correlateswith treatment response (efﬁcacy/toxic-
ity) in various cancers (Gao et al., 2012; Josephs et al., 2013). However,
the levels of evidence for TDM are heterogeneous among these agents,
and TDM is still uncommon for the majority of them. Evidence for ima-
tinib currently exists, while other lines of evidence are emerging for
compounds including nilotinib, dasatinib, erlotinib, sunitinib, sorafenib
and mammalian target of rapamycin inhibitors (Yu et al., 2014). Appli-
cations for TDM during oral targeted therapies may best be reserved for
particular situations, including lack of a therapeutic response, severe or
unexpected toxicities, unanticipated drug-drug interactions and/or con-
cerns over adherence to treatment.
4.1. Current dose
Table 3 describes the current dose of approved indications. As indi-
cated below, the initial doses of these TKIs are ﬁxed. Erlotinib is initiated
at 150 mg once daily in patients with NSCLC. The erlotinib dose is re-
duced to 100 mg once daily due to severe toxicities. The sorafenib
dose is reduced to 400 mg once daily and then to 400 mg every other
day with severe toxicities. Sunitinib was administered at a 50 mg
starting dose orally once daily for 4 weeks of a 6-week cycle for the
ﬁrst cycle in patients with RCC. Dose reductions to 37.5 mg daily and
then to 25 mg daily were permitted on the basis of individual tolerabil-
ity. Because pharmacokinetic variability of these drugs is very high,
ﬁxed dose regimens are considered to result in variation of the efﬁcacy
and side effects. Interpatient variabilities of these drugs are presented in
Table 3.
4.2. Target concentration
Table 4 describes the therapeutic target concentrations for each





51% Hidalgo and Bloedow, 2003
11-fold Akaza et al., 2007
54% Britten et al., 2008
ST: gastrointestinal stromal tumor.
Table 4
Target concentration of erlotinib, sorafenib, and sunitinib.
Target concentration References
Erotinib N500 ng/mL Hidalgo et al., 2001
Sorafenib Not clear
Sunitinib 50–100 ng/mL (total sunitinib) Mendel et al., 2003
Noda et al., in press
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concentration exceeding 500 μg/mL, a threshold required to achieve
EGFR inhibition and to prevent anti-proliferative activity (Hidalgo
et al., 2001). Clinical pharmacokinetic studies have supported an associ-
ation between the exposure to erlotinib and toxicity such as diarrhea
and skin rash (Hidalgo et al., 2001; Lu et al., 2006). We revealed that
the erlotinib trough concentration on day 8 was a signiﬁcant indepen-
dent predictor of grade ≥2 skin rash as well as diarrhea using multivar-
iate analysis (Fukudo et al., 2013). High exposure to erlotinib could force
the early discontinuation of treatment due to severe toxicities, resulting
in suboptimal efﬁcacy. In fact, it was reported that more patients were
forced to discontinue treatment due to intolerable toxicities during
the ﬁrst month in a high trough concentration group than in a low
trough concentration group in patients receiving erlotinib with NSCLC.
Recent studies have indicated that plasma cumulative exposure to
sorafenib is correlated with severe side effects (Boudou-Rouquette
et al., 2012a,b). However, large interpatient variability in sorafenib
pharmacokinetics has been observed (Minami et al., 2008). This may
be associated with slow dissolution in the gastrointestinal tract or satu-
ration of gastrointestinal absorption (Hornecker et al., 2012; Strumberg
et al., 2007). Sorafenib was shown to inhibit cell proliferation by 50% in
the human hepatocellular carcinoma cell lines PLC/PRF/5 and HepG2, at
concentrations of sorafenib of 2.09 μg/ml and 2.92 μg/ml, respectively
(Liu et al., 2006). Several clinical trials have also reported that the soraf-
enib concentration obtainedwith the currently accepted treatment reg-
imen (100–400 mg b.i.d.) ranged from 0.46 to 6.96 μg/ml (Duran et al.,
2007; Richly et al., 2006). A pharmacokinetic/pharmacodynamic study
reported the optimal cut-off concentrations of sorafenib to predict
grade ≥2 HFS (5.78 μg/mL) and hypertension (4.78 μg/mL) using receiv-
er operating characteristic curves in 52 patients (RCC, n= 16; HCC, n=
36) (Fukudo et al., 2014). In addition, HCC patients with sorafenib con-
centration of ≥4.78 μg/mL had longer overall survival than HCC patients
with b4.78 μg/mL (median 12.0 vs. 6.5 months, p = 0.0824). Further-
more, HCC patients showed signiﬁcantly higher dose-normalized con-
centrations than RCC patients (p = 0.0184). On the basis of these
ﬁndings, TDM of sorafenib could be useful to prevent severe toxicities,
resulting in improved clinical outcomes.
Preclinical studies have demonstrated that sunitinib is effective at
total plasma concentrations of 50–100 ng/ml (Mendel et al., 2003). A
clinical trial (Faivre et al., 2006) reported that the total sunitinib concen-
tration obtained with a dose of 50 mg daily ranged from 50 to
100 ng/ml. A phase II study also reported that sunitinib was effective
at plasma concentrations ≥50 ng/ml in Japanese patients with metasta-
tic RCC (Uemura et al., 2010). Therefore, the target range could be a total
sunitinib trough concentration of 50–100 ng/mL during sunitinib thera-
py. Sunitinib exposure appears to be associatedwith its therapeutic out-
come and/or toxicity. A meta-analysis showed that patients with
metastatic RCC, gastrointestinal stromal tumor (GIST) or solid tumors
and sunitinib AUC N800, 600 and 700 ng*hr/mL, respectively, had a lon-
ger time to progression and improved overall survival (Houk et al.,
2010). In GIST patients, the effect of gastrointestinal surgery on suniti-
nib pharmacokinetics is unknown. A recent study has shown that suni-
tinib and SU12662 exposure signiﬁcantly, although clinically not
relevantly, decreased in GIST patients whohad undergone both gastrec-
tomy and small bowel resection (de Wit et al., 2014). Therefore, the
TDM of sunitinib is useful for avoiding suboptimal efﬁcacy to sunitinib.
Recently, Lankheet et al. reported that a pharmacokinetic-guide dosingstrategy could be effective in advanced solid tumors (Lankheet et al.,
2014). In their study, patients were treated with sunitinib 37.5 mg
once daily. At days 15 and 29 of treatment, plasma trough levels of
total sunitinib were measured, and if the trough level was b50 ng/ml
and the patient did not show any grade 3 toxicity, the daily sunitinib
dosewas increased by 12.5mg. If the patient suffered from grade 3 tox-
icity, the sunitinib dose was lowered by 12.5 mg. As a result, total suni-
tinib concentrations were below the target in 15 patients (52%) at the
starting dose. Of these, ﬁve patients (17%) reached the target level
after dose escalation without additional toxicity. From these ﬁndings,
pharmacokinetic-guided dosing may lead to safer and more effective
treatment with sunitinib. Furthermore, we reported that RCC patients
with ≥100 ng/mL total sunitinib (n = 8), as compared with patients
with b100 ng/mL (n=13), had a higher incidence of Grade ≥3 toxicities
(75% vs. 23%) (Noda et al., in press). In this study, patients with
b100 ng/mL total sunitinib had signiﬁcantly longer time to treatment
failure (TTF), PFS than patients with ≥100 ng/mL (median TTF 590 vs.
71 days, P b 0.05;median PFS 748 vs. 238 days, P b 0.05). This study sug-
gests that therapeutic drug monitoring of sunitinib could be useful for
avoiding severe toxicities. Dose reduction may be needed, especially
when the total sunitinib concentration is ≥100 ng/mL, to avoid unneces-
sary early discontinuation of treatment.
4.3. Clinical application
TDM could be a powerful tool to identify drug-drug interactions
(van Leeuwen et al., 2014). Inducers of drug-metabolizing enzymes
have been shown to increase the systemic clearance of anticancer
agents, resulting in a lower effect (Mir et al., 2011; Relling et al.,
2000). For example, anticonvulsant drugs have been shown to in-
duce the metabolism of antileukemic agents and to decrease their
anticancer effects (Relling et al., 2000). In addition, a previous report
described a signiﬁcant metabolism-induced effect of fenoﬁbrate on
erlotinib, resulting in suboptimal exposure to erlotinib (Mir et al.,
2011). Against this background, drug-drug interaction in chemo-
therapy has become a serious problem. We reported a pharmacoki-
netic interaction between sorafenib and the CYP3A4 inducer
prednisolone in a patient with HCC (Noda et al., 2013). The concen-
tration of sorafenib was gradually increased following tapering of
prednisolone (Fig. 2A).
TDM could also be helpful in special populations. Most clinical trials
indicate renal function impairment as an exclusion criterion, so limited
data are available for patients on hemodialysis (HD). We investigated
the pharmacokinetics of erlotinib, sorafenib and sunitinib in dialyzed
patients (Noda et al., 2012; Shinsako et al., 2010; Togashi et al.,
2010a). As representative data, we analyzed a hemodialyzed patient
treated with 25 mg of sunitinib by a pharmacokinetic approach (Noda
et al., 2012). As shown in Fig. 2B, there were limited differences in the
AUC0–24 h of sunitinib and its major active metabolite SU12662 on day
17 (on HD) and day 18 (off HD) of the ﬁrst cycle. Collectively, we iden-
tiﬁed that erlotinib, sorafenib and sunitinib can become treatment op-
tions for hemodialyzed patients because the pharmacokinetics of
these agents is not affected by hemodialysis. This is because these
agents have similar characteristics, such as being metabolized by the
liver, and having high protein binding afﬁnity and high distribution
volume.
Brain metastases are seen in a number of patients with NSCLC. Pre-
vious studies have documented the effectiveness of geﬁtinib and erloti-
nib for the treatment of central nervous system (CNS) metastases of
NSCLC (Park et al., 2012). Erlotinib and geﬁtinib have weak CNS pene-
trance in NSCLC patients who developed leptomeningeal metastases
(Togashi et al., 2012). Several cases have been reported of CNSmetasta-
sis resistant to geﬁtinib being improved by erlotinib in patients with
NSCLC (Togashi et al., 2010b). Interestingly, the cerebrospinal ﬂuid
(CSF) concentration and penetration rate of erlotinib were signiﬁcantly
higher than those of geﬁtinib (Togashi et al., 2012). Additionally, ABCG2
A B
Fig. 2. A pharmacokinetic interaction between sorafenib and prednisolone. A patient with HCCwas treated with sorafenib at 400mg daily concurrently with oral prednisolone, a CYP3A4
inducer. The concentration of sorafenib gradually increased following the tapering of prednisolone. This observation indicates that prednisolone stimulates sorafenib metabolism. B The
effect of hemodialysis on sunitinib pharmacokinetics. Sunitinib concentration was not affected by hemodialysis. Arrows indicate the administration of sunitinib. Pink area shows the ther-
apeutic range of sunitinib (50–100 ng/ml) (Mendel et al., 2003). HD: hemodialysis.
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CSF concentrations of erlotinib and OSI-420 (Fukudo et al., 2013).
This may be because ABCG2 limits the brain distribution of erlotinib
and OSI-420 at the BBB in cancer patients. Therefore, TDM of the CSF
concentration of erlotinib based on ABCG2 variant could be effective
for the treatment of CNS metastases, especially leptomeningeal me-
tastases. However, optimal concentrations of erlotinib have not been
identiﬁed.
5. Molecular mechanisms of skin disorder
In clinical practice, TKIs are believed to be better tolerated than con-
ventional cytotoxic chemotherapies, but they frequently cause various
ADRs such as skin disorders, hypertension, proteinuria, interstitial
pneumonia and diarrhea. These ADRs often cause treatment discontin-
uation or dose reduction, which has been considered to be a critical
problem in treatment with TKIs. To overcome these problems, various
studies have been carried out to understand the mechanisms of ADRs.
Among ADRs, extensive efforts have beenmade to clarify the molecular
mechanisms of skin disorders, such as hand-foot skin reaction (HFSR).
This is because the mechanisms of this ADR are poorly understood,
and it is known to have amajor impact on the quality of life (QOL) of pa-
tients. In the case of sorafenib therapy, Grade ≥2 HFSR causes painful er-
ythema, edema and desquamation of the palms and soles, which can
lead to limitation in the activities of daily living and decreased QOL
(Kim et al., 2011). Current strategies for skin disorders involve symp-
tomatic therapy based on clinical experience, but an understanding of
the molecular mechanisms should lead to the development of novel
strategies to control the pathogenic mechanisms of the toxic effects on
the skin.
5.1. Erlotinib
It has been demonstrated that targeted therapies do not work only
through action on the originally designed molecular target. This effect
was called as off-target effect. A few reports have described the unantic-
ipated effects caused by the inhibition of off-target kinases. For example,
although imatinib was designed to speciﬁcally target BCR-Abl, it has
been suggested that imatinib has direct effects on bone-resorbing oste-
oclasts and bone-forming osteoblasts through the off-target inhibition
of c-fms, c-kit, carbonic anhydrase II, and platelet-derived growth factor
receptor (Vandyke et al., 2010).
The pathophysiology of EGFR inhibitor-associated skin disorder is
not completely understood. Inhibition of EGFR-mediated signalpathways induces multiple effects in basal keratinocytes, including
growth arrest, decreased migration, increased cell attachment, ab-
normal differentiation and stimulation of inﬂammatory systems, all
of which result in distinctive cutaneous manifestations (Mascia
et al., 2003; Woodworth et al., 2005). However, it has been unclear
whether off-target inhibition by erlotinib plays a role in the side ef-
fects of erlotinib. Interestingly, a recent study demonstrated that
the off-target serine/threonine kinase 10 (STK10) is inhibited much
more potently by erlotinib than by geﬁtinib under clinical conditions
(Yamamoto et al., 2011). Furthermore, in vitro experiments showed
that erlotinib enhanced lymphocytic responses such as cell migra-
tion and interleukin-2 secretion via SKT10 inhibition. Additionally,
in vivo observations were consistent with these in vitro results.
These ﬁndings suggested that erlotinib exacerbates skin disorders
through off-target kinase inhibition, and may partly explain the dif-
ference of the severity of skin disorders between erlotinib and
geﬁtinib.5.2. Sorafenib and sunitinib
Sorafenib and sunitinib are also associatedwith various dermatolog-
ical toxicities. The administration of sorafenib and sunitinib is common-
ly associated with HFSR, but the exact mechanisms of HFSR with these
drugs are not fully understood. Several hypotheses have been reported:
(I) an increased drug concentration in the capillaries at the papillary
dermis, (II) interference by vascular endothelial growth factor-PDGFR
inhibition associated with pericyte-mediated endothelial survival
mechanisms, leading to damage of the capillary endothelium in hands
and feet, (III) impaired vascular repair leading to keratinocyte apoptosis
and inﬂammation and (IV) a direct effect of the drug on eccrine sweat
glands (Chan et al., 2014). Sorafenib inhibits signal transducer and acti-
vator of transcription 3 (STAT3) downstreamof the EGFR (Siegelin et al.,
2010; Yang et al., 2010). STAT3 has been reported to be the main factor
in the molecular control of cutaneous homeostasis (Levy and Darnell,
2002; Quadros et al., 2004). Recently, a basic study demonstrated that
the toxicity of sorafenib and sunitinib to keratinocytes was induced by
decreased apoptosis suppressor via the inhibition of STAT3 activity
(Yamamoto et al., 2014). Interestingly, sorafenib-induced STAT3 inhibi-
tion was mediated by regulation via the mitogen-activated protein ki-
nase pathway in HaCaT cells, while sunitinib-induced inhibition was
not. From these ﬁndings, STAT3 activation mediating apoptosis sup-
pressors may be a key factor in sorafenib and sunitinib-induced
keratinocyte cytotoxicity.
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In this commentary, we describe recent pharmacological ﬁndings
about the oral TKIs, focusing on erlotinib, sorafenib and sunitinib, re-
garding their drug-metabolizing enzymes and transporters, factors
causing pharmacokinetic variation, TDM and the molecular mecha-
nisms of skin disorders. The pharmacokinetic parameters of these TKIs
have been demonstrated to be associated with drug efﬁcacy and toxic-
ities. Additionally, these pharmacokinetic variations may be caused by
genetic variants of ABCG2, especially erlotinib and sunitinib. Thus, phar-
macokinetic and pharmacogenomic assessment of TKIs could be useful
for the evaluation and prediction of their outcomes, severe side effects
and drug-drug interactions. Furthermore, an understanding of the
mechanisms of skin toxicity induced by TKIs, which lead to dose reduc-
tion or discontinuation,will help us to establish appropriatemedication.
In the near future, the information obtained could play a prominent role
in personalized medicine in TKI treatment.Conﬂict of Interest Statement
T. Terada, S. Noda and K. Inui have declared no potential conﬂicts of
interest.Acknowledgments
Work in the authors' laboratory is supported byGrant-in-Aid for Sci-
entiﬁc Research from the Japanese Ministry of Education, Culture,
Sports, Science and Technology.References
Adams, V. R., & Leggas, M. (2007). Sunitinib malate for the treatment of metastatic renal
cell carcinoma and gastrointestinal stromal tumors. Clin Ther 29(7), 1338–1353.
Agarwal, S., Sane, R., Gallardo, J. L., Ohlfest, J. R., & Elmquist, W. F. (2010). Distribution of
geﬁtinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resis-
tance protein (ABCG2)-mediated active efﬂux. J Pharmacol Exp Ther 334(1), 147–155.
Akaza, H., Tsukamoto, T., Murai, M., Nakajima, K., & Naito, S. (2007). Phase II study to in-
vestigate the efﬁcacy, safety, and pharmacokinetics of sorafenib in Japanese patients
with advanced renal cell carcinoma. Jpn J Clin Oncol 37(10), 755–762.
Baker, S. D., Verweij, J., Rowinsky, E. K., Donehower, R. C., Schellens, J. H., Grochow, L. B.,
et al. (2002). Role of body surface area in dosing of investigational anticancer agents
in adults, 1991–2001. J Natl Cancer Inst 94(24), 1883–1888.
Bello, C. L., Sherman, L., Zhou, J., Verkh, L., Smeraglia, J., Mount, J., et al. (2006). Effect of
food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted recep-
tor tyrosine kinase inhibitor: results from a phase I Study in healthy subjects.
Anticancer Drugs 17(3), 353–358.
Bezjak, A., Tu, D., Seymour, L., Clark, G., Trajkovic, A., Zukin, M., et al. (2006). Symptom im-
provement in lung cancer patients treatedwith erlotinib: quality of life analysis of the
National Cancer Institute of Canada Clinical Trials Group Study Br.21. J Clin Oncol
24(24), 3831–3837.
Boudou-Rouquette, P., Narjoz, C., Golmard, J. L., Thomas-Schoemann, A., Mir, O., Taieb, F.,
et al. (2012a). Early sorafenib-induced toxicity is associated with drug exposure and
UGT1A9 genetic polymorphism in patients with solid tumors: a preliminary study.
PLoS One 7(8), e42875.
Boudou-Rouquette, P., Ropert, S., Mir, O., Coriat, R., Billemont, B., Tod, M., et al. (2012b).
Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharma-
codynamic analysis. Oncologist 17(9), 1204–1212.
Britten, C. D., Kabbinavar, F., Hecht, J. R., Bello, C. L., Li, J., Baum, C., et al. (2008). A phase I
and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a
1-week off period. Cancer Chemother Pharmacol 61(3), 515–524.
Budha, N. R., Frymoyer, A., Smelick, G. S., Jin, J. Y., Yago, M. R., Dresser, M. J., et al. (2012).
Drug absorption interactions between oral targeted anticancer agents and PPIs: is
pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther
92(2), 203–213.
Chan, A., Lees, J., & Keefe, D. (2014). The changing paradigm for supportive care in cancer
patients. Support Care Cancer 22(6), 1441–1445.
Cheng, A. L., Kang, Y. K., Chen, Z., Tsao, C. J., Qin, S., Kim, J. S., et al. (2009). Efﬁcacy and safe-
ty of sorafenib in patients in the Asia-Paciﬁc regionwith advanced hepatocellular car-
cinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol
10(1), 25–34.
Clark, J.W., Eder, J. P., Ryan, D., Lathia, C., & Lenz, H. J. (2005). Safety and pharmacokinetics
of the dual action Raf kinase and vascular endothelial growth factor receptor inhibi-
tor, BAY 43–9006, in patients with advanced, refractory solid tumors. Clin Cancer Res
11(15), 5472–5480.de Wit, D., van Erp, N. P., Khosravan, R., Wiltshire, R., Allred, R., Demetri, G. D., et al.
(2014). Effect of gastrointestinal resection on sunitinib exposure in patients with
GIST. BMC Cancer 14, 575.
Diekstra, M. H., Klümpen, H. J., Lolkema, M. P., Yu, H., Kloth, J. S., Gelderblom, H., et al.
(2014). Association analysis of genetic polymorphisms in genes related to sunitinib
pharmacokinetics, speciﬁcally clearance of sunitinib and SU12662. Clin Pharmacol
Ther 96(1), 81–89.
Duong, S., & Leung, M. (2011). Should the concomitant use of erlotinib and acid-reducing
agents be avoided? The drug interaction between erlotinib and acid-reducing agents.
J Oncol Pharm Pract 17(4), 448–452.
Duran, I., Hotté, S. J., Hirte, H., Chen, E. X., MacLean, M., Turner, S., et al. (2007). Phase I
targeted combination trial of sorafenib and erlotinib in patients with advanced
solid tumors. Clin Cancer Res 13(16), 4849–4857.
Elmeliegy, M. A., Carcaboso, A. M., Tagen, M., Bai, F., & Stewart, C. F. (2011). Role of ATP-
binding cassette and solute carrier transporters in erlotinib CNS penetration and in-
tracellular accumulation. Clin Cancer Res 17(1), 89–99.
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., et al. (2006). Safety, phar-
macokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine ki-
nase inhibitor, in patients with cancer. J Clin Oncol 24(1), 25–35.
Fujita, K., Hirose, T., Kusumoto, S., Sugiyama, T., Shirai, T., Nakashima, M., et al. (2014).
High exposure to erlotinib and severe drug-induced interstitial lung disease in pa-
tients with non-small-cell lung cancer. Lung Cancer 86(1), 113–114.
Fukudo, M., Ikemi, Y., Togashi, Y., Masago, K., Kim, Y. H., Mio, T., et al. (2013). Population
pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of
plasma and cerebrospinal ﬂuid drug concentrations in Japanese patients with non-
small cell lung cancer. Clin Pharmacokinet 52(7), 593–609.
Fukudo, M., Ito, T., Mizuno, T., Shinsako, K., Hatano, E., Uemoto, S., et al. (2014). Exposure-
toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and
hepatocellular carcinoma. Clin Pharmacokinet 53(2), 185–196.
Furukawa, T., Wakabayashi, K., Tamura, A., Nakagawa, H., Morishima, Y., Osawa, Y., et al.
(2009). Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes ly-
sosomal and proteasomal degradations. Pharm Res 26(2), 469–479.
Gao, B., Yeap, S., Clements, A., Balakrishnar, B., Wong, M., & Gurney, H. (2012). Evidence
for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol
30(32), 4017–4025.
Garcia-Donas, J., Esteban, E., Leandro-García, L. J., Castellano, D. E., del Alba, A. G., Climent,
M. A., et al. (2011). Single nucleotide polymorphism associations with response and
toxic effects in patients with advanced renal-cell carcinoma treated with ﬁrst-line su-
nitinib: a multicentre, observational, prospective study. Lancet Oncol 12(12),
1143–1150.
Giacomini, K. M., Balimane, P. V., Cho, S. K., Eadon, M., Edeki, T., Hillgren, K. M., et al.
(2013). International Transporter Consortium commentary on clinically important
transporter polymorphisms. Clin Pharmacol Ther 94(1), 23–26.
Glavinas, H., Krajcsi, P., Cserepes, J., & Sarkadi, B. (2004). The Role of ABC transporters in
drug resistance, metabolism and toxicity. Curr Drug Deliv 1(1), 27–42.
Gnoth, M. J., Sandmann, S., Engel, K., & Radtke, M. (2010). In vitro to in vivo comparison of
the substrate characteristics of sorafenib tosylate toward P-glycoprotein. Drug Metab
Dispos 38(8), 1341–1346.
Gomo, C., Coriat, R., Faivre, L., Mir, O., Ropert, S., Billemont, B., et al. (2011). Pharmacoki-
netic interaction involving sorafenib and the calcium-channel blocker felodipine in a
patient with hepatocellular carcinoma. Invest New Drugs 29(6), 1511–1514.
Gore, M. E., Szczylik, C., Porta, C., Bracarda, S., Bjarnason, G. A., Oudard, S., et al. (2009).
Safety and efﬁcacy of sunitinib for metastatic renal-cell carcinoma: an expanded-
access trial. Lancet Oncol 10(8), 757–763.
Hamada, A., Sasaki, J., Saeki, S., Iwamoto, N., Inaba, M., Ushijima, S., et al. (2012). Associa-
tion of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in
Japanese patients with non-small-cell lung cancer. Pharmacogenomics 13(5),
615–624.
Hamilton, M., Wolf, J. L., Rusk, J., Beard, S. E., Clark, G. M., Witt, K., et al. (2006). Effects of
smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 12(7)(Pt 1),
2166–2171.
Herraez, E., Lozano, E., Macias, R. I., Vaquero, J., Bujanda, L., Banales, J. M., et al. (2013). Ex-
pression of SLC22A1 variants may affect the response of hepatocellular carcinoma
and cholangiocarcinoma to sorafenib. Hepatology 58(3), 1065–1073.
Hidalgo, M., & Bloedow, D. (2003). Pharmacokinetics and pharmacodynamics: maximiz-
ing the clinical potential of Erlotinib (Tarceva). Semin Oncol 30(3)(Suppl. 7), 25–33.
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., et al. (2001).
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor ty-
rosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol
19(13), 3267–3279.
Hong, M. H., Kim, H. S., Kim, C., Ahn, J. R., Chon, H. J., Shin, S. J., et al. (2009). Treatment
outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single
cancer center experience in Korea. Cancer Res Treat 41(2), 67–72.
Hornecker, M., Blanchet, B., Billemont, B., Sassi, H., Ropert, S., Taieb, F., et al. (2012). Satu-
rable absorption of sorafenib in patients with solid tumors: a population model.
Invest New Drugs 30(5), 1991–2000.
Houk, B. E., Bello, C. L., Kang, D., & Amantea, M. (2009). A population pharmacokinetic
meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662)
in healthy volunteers and oncology patients. Clin Cancer Res 15(7), 2497–2506.
Houk, B. E., Bello, C. L., Poland, B., Rosen, L. S., Demetri, G. D., & Motzer, R. J. (2010). Rela-
tionship between exposure to sunitinib and efﬁcacy and tolerability endpoints in pa-
tients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Cancer Chemother Pharmacol 66(2), 357–371.
Hu, S., Chen, Z., Franke, R., Orwick, S., Zhao, M., Rudek, M. A., et al. (2009). Interaction of
the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-
Binding cassette transporters. Clin Cancer Res 15(19), 6062–6069.
133T. Terada et al. / Pharmacology & Therapeutics 152 (2015) 125–134Jain, L., Woo, S., Gardner, E. R., Dahut, W. L., Kohn, E. C., Kummar, S., et al. (2011). Popula-
tion pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin
Pharmacol 72(2), 294–305.
Johnson, J. R., Cohen,M., Sridhara, R., Chen, Y. F., Williams, G. M., Duan, J., et al. (2005). Ap-
proval summary for erlotinib for treatment of patients with locally advanced or met-
astatic non-small cell lung cancer after failure of at least one prior chemotherapy
regimen. Clin Cancer Res 11(18), 6414–6421.
Josephs, D. H., Fisher, D. S., Spicer, J., & Flanagan, R. J. (2013). Clinical pharmacokinetics of
tyrosine kinase inhibitors: implications for therapeutic drug monitoring. Ther Drug
Monit 35(5), 562–587.
Kane, R. C., Farrell, A. T., Saber, H., Tang, S., Williams, G., Jee, J. M., et al. (2006). Sorafenib
for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12(24),
7271–7278.
Keating, G. M., & Santoro, A. (2009). Sorafenib: a review of its use in advanced hepatocel-
lular carcinoma. Drugs 69(2), 223–240.
Kim, H. R., Park, H. S., Kwon, W. S., Lee, J. H., Tanigawara, Y., Lim, S. M., et al. (2013). Phar-
macogenetic determinants associated with sunitinib-induced toxicity and ethnic dif-
ference in Korean metastatic renal cell carcinoma patients. Cancer Chemother
Pharmacol 72(4), 825–835.
Kim, D. H., Son, I. P., Lee, J. W., Lee, H. I., Kim, B. J., & Kim, M. N. (2011). Sorafenib
(Nexavar®, BAY 43–9006)-induced hand-foot skin reaction with facial erythema.
Ann Dermatol 23(1), 119–122.
Kimchi-Sarfaty, C., Oh, J. M., Kim, I. W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., et al.
(2007). A "silent" polymorphism in the MDR1 gene changes substrate speciﬁcity.
Science 315(5811), 525–528.
Klümpen, H. J., Samer, C. F., Mathijssen, R. H., Schellens, J. H., & Gurney, H. (2011). Moving
towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev 37(4),
251–260.
Kodaira, H., Kusuhara, H., Ushiki, J., Fuse, E., & Sugiyama, Y. (2010). Kinetic analysis of the
cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein
(Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, ﬂavopiridol,
and mitoxantrone. J Pharmacol Exp Ther 333(3), 788–796.
Kunimatsu, S., Mizuno, T., Fukudo, M., & Katsura, T. (2013). Effect of P-glycoprotein and
breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in
rats. Drug Metab Dispos 41(8), 1592–1597.
Lagas, J. S., vanWaterschoot, R. A., Sparidans, R.W.,Wagenaar, E., Beijnen, J. H., & Schinkel,
A. H. (2010). Breast cancer resistance protein and P-glycoprotein limit sorafenib brain
accumulation. Mol Cancer Ther 9(2), 319–326.
Lankheet, N. A., Kloth, J. S., Gadellaa-van Hooijdonk, C. G., Cirkel, G. A., Mathijssen, R. H.,
Lolkema, M. P., et al. (2014). Pharmacokinetically guided sunitinib dosing: a feasibil-
ity study in patients with advanced solid tumours. Br J Cancer 110(10), 2441–2449.
Lathia, C., Lettieri, J., Cihon, F., Gallentine, M., Radtke, M., & Sundaresan, P. (2006). Lack of
effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacoki-
netics. Cancer Chemother Pharmacol 57(5), 685–692.
Levy, D. E., & Darnell, J. E. (2002). Stats: transcriptional control and biological impact. Nat
Rev Mol Cell Biol 3(9), 651–662.
Li, J., Cusatis, G., Brahmer, J., Sparreboom, A., Robey, R. W., Bates, S. E., et al. (2007a). As-
sociation of variant ABCG2 and the pharmacokinetics of epidermal growth factor re-
ceptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6(3), 432–438.
Li, J., Zhao, M., He, P., Hidalgo, M., & Baker, S. D. (2007b). Differential metabolism of geﬁ-
tinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 13(12),
3731–3737.
Ling, J., Fettner, S., Lum, B. L., Riek, M., & Rakhit, A. (2008). Effect of food on the pharma-
cokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-
kinase inhibitor, in healthy individuals. Anticancer Drugs 19(2), 209–216.
Ling, J., Johnson, K. A., Miao, Z., Rakhit, A., Pantze, M. P., Hamilton, M., et al. (2006). Metab-
olism and excretion of erlotinib, a small molecule inhibitor of epidermal growth fac-
tor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 34(3),
420–426.
Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., et al. (2006). Sorafenib blocks
the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell ap-
optosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66(24),
11851–11858.
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., et al. (2008). Sorafenib
in advanced hepatocellular carcinoma. N Engl J Med 359(4), 378–390.
Lu, J. F., Eppler, S. M., Wolf, J., Hamilton, M., Rakhit, A., Bruno, R., et al. (2006). Clinical
pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety rela-
tionship in patients with non-small cell lung cancer. Clin Pharmacol Ther 80(2),
136–145.
Marchetti, S., de Vries, N. A., Buckle, T., Bolijn, M. J., van Eijndhoven, M. A., Beijnen, J. H.,
et al. (2008). Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2,
and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo
pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout)
and wild-type mice. Mol Cancer Ther 7(8), 2280–2287.
Marin, D., Bazeos, A., Mahon, F. X., Eliasson, L., Milojkovic, D., Bua, M., et al. (2010). Adher-
ence is the critical factor for achieving molecular responses in patients with chronic
myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin
Oncol 28(14), 2381–2388.
Mascia, F., Mariani, V., Girolomoni, G., & Pastore, S. (2003). Blockade of the EGF receptor
induces a deranged chemokine expression in keratinocytes leading to enhanced
skin inﬂammation. Am J Pathol 163(1), 303–312.
Mendel, D. B., Laird, A. D., Xin, X., Louie, S. G., Christensen, J. G., Li, G., et al. (2003). In vivo
antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular
endothelial growth factor and platelet-derived growth factor receptors: determina-
tion of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1),
327–337.Minami, H., Kawada, K., Ebi, H., Kitagawa, K., Kim, Y. I., Araki, K., et al. (2008). Phase I and
pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese pa-
tients with advanced refractory solid tumors. Cancer Sci 99(7), 1492–1498.
Mir, O., Blanchet, B., & Goldwasser, F. (2011). Drug-induced effects on erlotinib metabo-
lism. N Engl J Med 365(4), 379–380.
Mizuno, T., Fukudo, M., Fukuda, T., Terada, T., Dong, M., Kamba, T., et al. (2014). The effect
of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with
renal cell carcinoma. Ther Drug Monit 36(3), 310–316.
Mizuno, T., Fukudo, M., Terada, T., Kamba, T., Nakamura, E., Ogawa, O., et al. (2012). Im-
pact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on suniti-
nib pharmacokinetics. Drug Metab Pharmacokinet 27(6), 631–639.
Mizuno, T., Terada, T., Kamba, T., Fukudo, M., Katsura, T., Nakamura, E., et al. (2010).
ABCG2 421C N A polymorphism and high exposure of sunitinib in a patient with
renal cell carcinoma. Ann Oncol 21(6), 1382–1383.
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., et al.
(2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J
Med 356(2), 115–124.
Noda, S., Kageyama, S., Tsuru, T., Kubota, S., Yoshida, T., Okamoto, K., et al. (2012). Phar-
macokinetic/pharmacodynamic analysis of a hemodialyzed patient treated with
25 mg of sunitinib. Case Rep Oncol 5(3), 627–632.
Noda, S., Otusji, T., Baba, M., Yoshida, T., Kageyama, S., Okamoto, K., et al. (2015). Assess-
ment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug
monitoring of sunitinib for patients with renal cell carcinoma. Clin Genitourin Cancer
(in press).
Noda, S., Shioya, M., Hira, D., Fujiyama, Y., Morita, S. Y., & Terada, T. (2013). Pharmacoki-
netic interaction between sorafenib and prednisolone in a patientwith hepatocellular
carcinoma. Cancer Chemother Pharmacol 72(1), 269–272.
Noens, L., van Lierde, M. A., De Bock, R., Verhoef, G., Zachée, P., Berneman, Z., et al. (2009).
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in pa-
tients with chronic myeloid leukemia: the ADAGIO study. Blood 113(22), 5401–5411.
Oostendorp, R. L., Buckle, T., Beijnen, J. H., van Tellingen, O., & Schellens, J. H. (2009). The
effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo ab-
sorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 27(1),
31–40.
Park, S. J., Kim, H. T., Lee, D. H., Kim, K. P., Kim, S. W., Suh, C., et al. (2012). Efﬁcacy of epi-
dermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-
small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer
77(3), 556–560.
Polli, J. W., Olson, K. L., Chism, J. P., John-Williams, L. S., Yeager, R. L., Woodard, S. M.,
et al. (2009). An unexpected synergist role of P-glycoprotein and breast cancer
resistance protein on the central nervous system penetration of the tyrosine kinase
inhibitor lapatinib (N-{3-chloro-4-[(3-ﬂuorobenzyl)oxy]phenyl}-6-[5-({[2-
(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016).
Drug Metab Dispos 37(2), 439–442.
Quadros, M. R., Peruzzi, F., Kari, C., & Rodeck, U. (2004). Complex regulation of signal
transducers and activators of transcription 3 activation in normal and malignant
keratinocytes. Cancer Res 64(11), 3934–3939.
Rakhit, A., Pantze, M. P., Fettner, S., Jones, H. M., Charoin, J. E., Riek, M., et al. (2008).
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based
simulation (SimCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol
64(1), 31–41.
Relling, M. V., Pui, C. H., Sandlund, J. T., Rivera, G. K., Hancock, M. L., Boyett, J. M., et al.
(2000). Adverse effect of anticonvulsants on efﬁcacy of chemotherapy for acute lym-
phoblastic leukaemia. Lancet 356(9226), 285–290.
Richly, H., Henning, B. F., Kupsch, P., Passarge, K., Grubert, M., Hilger, R. A., et al. (2006).
Results of a phase I trial of sorafenib (BAY 43–9006) in combination with doxorubicin
in patients with refractory solid tumors. Ann Oncol 17(5), 866–873.
Rudin, C. M., Liu, W., Desai, A., Karrison, T., Jiang, X., Janisch, L., et al. (2008).
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin
Oncol 26(7), 1119–1127.
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S.,
et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J
Med 353(2), 123–132.
Shinsako, K., Mizuno, T., Terada, T., Watanabe, J., Kamba, T., Nakamura, E., et al. (2010).
Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a
case study. Int J Clin Oncol 15(5), 512–514.
Siegelin, M. D., Raskett, C. M., Gilbert, C. A., Ross, A. H., & Altieri, D. C. (2010). Sorafenib ex-
erts anti-glioma activity in vitro and in vivo. Neurosci Lett 478(3), 165–170.
Sparreboom, A., Gelderblom, H., Marsh, S., Ahluwalia, R., Obach, R., Principe, P., et al.
(2004). Diﬂomotecan pharmacokinetics in relation to ABCG2 421C N A genotype.
Clin Pharmacol Ther 76(1), 38–44.
Strumberg, D., Clark, J. W., Awada, A., Moore, M. J., Richly, H., Hendlisz, A., et al. (2007).
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review
of four phase I trials in patients with advanced refractory solid tumors. Oncologist
12(4), 426–437.
Swift, B., Nebot, N., Lee, J. K., Han, T., Proctor, W. R., Thakker, D. R., et al. (2013). Sorafenib
hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generat-
ed metabolites. Drug Metab Dispos 41(6), 1179–1186.
Tang, S. C., de Vries, N., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H.
(2013). Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein
(ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of
dasatinib, sorafenib, and sunitinib. J Pharmacol Exp Ther 346(3), 486–494.
Tang, S. C., Lankheet, N. A., Poller, B., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2012).
P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain
accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol
Exp Ther 341(1), 164–173.
134 T. Terada et al. / Pharmacology & Therapeutics 152 (2015) 125–134Thomas, F., Rochaix, P., White-Koning, M., Hennebelle, I., Sarini, J., Benlyazid, A., et al.
(2009). Population pharmacokinetics of erlotinib and Its pharmacokinetic/pharmaco-
dynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer
45(13), 2316–2323.
Togashi, Y., Masago, K., Fukudo, M., Terada, T., Fujita, S., Irisa, K., et al. (2010a). Cerebrospi-
nal ﬂuid concentration of erlotinib and its active metabolite OSI-420 in patients with
central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 7,
950–955.
Togashi, Y., Masago, K., Fukudo, M., Terada, T., Ikemi, Y., Kim, Y. H., et al. (2010b). Pharma-
cokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small
cell lung cancer and chronic renal failure who are undergoing hemodialysis. J
Thorac Oncol 5(5), 601–605.
Togashi, Y., Masago, K., Masuda, S., Mizuno, T., Fukudo, M., Ikemi, Y., et al. (2012). Cere-
brospinal ﬂuid concentration of geﬁtinib and erlotinib in patients with non-small
cell lung cancer. Cancer Chemother Pharmacol 70(3), 399–405.
Uemura, H., Shinohara, N., Yuasa, T., Tomita, Y., Fujimoto, H., Niwakawa, M., et al. (2010).
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcino-
ma: insights into the treatment, efﬁcacy and safety. Jpn J Clin Oncol 40(3), 194–202.
van der Veldt, A. A., Eechoute, K., Gelderblom, H., Gietema, J., Guchelaar, H. J., van Erp, N.
P., et al. (2011). Genetic polymorphisms associated with a prolonged progression-
free survival in patients with metastatic renal cell cancer treated with sunitinib.
Clin Cancer Res 17(3), 620–629.
van Erp, N. P., Baker, S. D., Zandvliet, A. S., Ploeger, B. A., den Hollander, M., Chen, Z., et al.
(2011). Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemother
Pharmacol 67(3), 695–703.
van Erp, N. P., Eechoute, K., van der Veldt, A. A., Haanen, J. B., Reyners, A. K., Mathijssen, R.
H., et al. (2009). Pharmacogenetic pathway analysis for determination of sunitinib-
induced toxicity. J Clin Oncol 27(26), 4406–4412.
van Leeuwen, R. W., van Gelder, T., Mathijssen, R. H., & Jansman, F. G. (2014). Drug-drug
interactionswith tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 15(8),
e315–e326.
Vandyke, K., Fitter, S., Dewar, A. L., Hughes, T. P., & Zannettino, A. C. (2010). Dysregulation
of bone remodeling by imatinib mesylate. Blood 115(4), 766–774.
White-Koning, M., Civade, E., Geoerger, B., Thomas, F., Le Deley, M. C., Hennebelle, I., et al.
(2011). Population analysis of erlotinib in adults and children reveals pharmacokineticcharacteristics as the main factor explaining tolerance particularities in children. Clin
Cancer Res 17(14), 4862–4871.
Woodworth, C. D., Michael, E., Marker, D., Allen, S., Smith, L., & Nees, M. (2005). Inhibition
of the epidermal growth factor receptor increases expression of genes that stimulate
inﬂammation, apoptosis, and cell attachment. Mol Cancer Ther 4(4), 650–658.
Yamamoto, N., Honma, M., & Suzuki, H. (2011). Off-Target serine/threonine kinase 10 in-
hibition by erlotinib enhances lymphocytic activity leading to severe skin disorders.
Mol Pharmacol 80(3), 466–475.
Yamamoto, K., Mizumoto, A., Nishimura, K., Uda, A., Mukai, A., Yamashita, K., et al. (2014).
Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhi-
bition of signal transduction and activator of transcription 3 (STAT3). PLoS One 9(7),
e102110.
Yamasaki, Y., Ieiri, I., Kusuhara, H., Sasaki, T., Kimura, M., Tabuchi, H., et al. (2008). Phar-
macogenetic characterization of sulfasalazine disposition based on NAT2 and
ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther 84(1), 95–103.
Yang, F., Brown, C., Buettner, R., Hedvat, M., Starr, R., Scuto, A., et al. (2010). Sorafenib in-
duces growth arrest and apoptosis of human glioblastoma cells through the dephos-
phorylation of signal transducers and activators of transcription 3. Mol Cancer Ther
9(4), 953–962.
Yoo, C., Kim, J. E., Lee, J. L., Ahn, J. H., Lee, D. H., Lee, J. S., et al. (2010). The efﬁcacy and safe-
ty of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence
of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 40(10), 980–985.
Yu, H., Steeghs, N., Nijenhuis, C. M., Schellens, J. H., Beijnen, J. H., & Huitema, A. D. (2014).
Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase in-
hibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet 53(4), 305–325.
Zhang, L., Wu, F., Lee, S. C., & Zhao, H. (2014). pH-dependent drug-drug interactions for
weak base drugs: potential implications for new drug development. Clin Pharmacol
Ther 96(2), 266–277.
Zhang, W., Yu, B. N., He, Y. J., Fan, L., Li, Q., Liu, Z. Q., et al. (2006). Role of BCRP 421C N A
polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim
Acta 373(1–2), 99–103.
Zimmerman, E. I., Hu, S., Roberts, J. L., Gibson, A. A., Orwick, S. J., Li, L., et al. (2013). Con-
tribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-
glucuronide. Clin Cancer Res 19(6), 1458–1466.
